deltatrials
Completed PHASE2 NCT00005878

Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus

Chemoprevention for Barrett's Esophagus Trial (CBET)

Sponsor: National Cancer Institute (NCI)

Interventions celecoxib
Updated 5 times since 2017 Last updated: Oct 12, 2016 Started: Jul 31, 2000 Primary completion: Sep 30, 2005 Completion: Sep 30, 2005

A PHASE2 clinical study on Esophageal Cancer, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 5 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted

Change History

5 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jul 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Data source: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

For direct contact, visit the study record on ClinicalTrials.gov .